Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel

Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel

Parkinson’s disease is a progressive neurodegenerative disorder in which loss of dopaminergic neurons in the substantia nigra results in a clinically heterogeneous group with variable motor and non-motor symptoms with a degree of misdiagnosis. Only 3–25% of sporadic Parkinson’s patients present with...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 14; no. 1; p. 10036
Main Authors: Peng, Kuan-Wei, Klotz, Allison, Guven, Arcan, Kapadnis, Unnati, Ravipaty, Shobha, Tolstikov, Vladimir, Vemulapalli, Vijetha, Rodrigues, Leonardo O., Li, Hongyan, Kellogg, Mark D., Kausar, Farah, Rees, Linda, Sarangarajan, Rangaprasad, Schüle, Birgitt, Langston, William, Narain, Paula, Narain, Niven R., Kiebish, Michael A.
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 02-05-2024
Nature Publishing Group
Nature Portfolio
Subjects:
631/1647/320
692/53/2421
692/53/2423
692/699/375
Aged
Biomarkers
Biomarkers - blood
Case-Control Studies
Dopamine receptors
Female
Genetic abnormalities
Humanities and Social Sciences
Humans
Male
Middle Aged
multidisciplinary
Neurodegenerative diseases
Neurological diseases
Olfaction
Parkinson Disease - diagnosis
Parkinson's disease
Prospective Studies
Putrescine
Putrescine - analogs & derivatives
Risk factors
Science
Science (multidisciplinary)
Substantia nigra
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson’s disease is a progressive neurodegenerative disorder in which loss of dopaminergic neurons in the substantia nigra results in a clinically heterogeneous group with variable motor and non-motor symptoms with a degree of misdiagnosis. Only 3–25% of sporadic Parkinson’s patients present with genetic abnormalities that could represent a risk factor, thus environmental, metabolic, and other unknown causes contribute to the pathogenesis of Parkinson’s disease, which highlights the critical need for biomarkers. In the present study, we prospectively collected and analyzed plasma samples from 194 Parkinson’s disease patients and 197 age-matched non-diseased controls. N -acetyl putrescine (NAP) in combination with sense of smell (B-SIT), depression/anxiety (HADS), and acting out dreams (RBD1Q) clinical measurements demonstrated combined diagnostic utility. NAP was increased by 28% in Parkinsons disease patients and exhibited an AUC of 0.72 as well as an OR of 4.79. The clinical and NAP panel demonstrated an area under the curve, AUC = 0.9 and an OR of 20.4. The assessed diagnostic panel demonstrates combinatorial utility in diagnosing Parkinson’s disease, allowing for an integrated interpretation of disease pathophysiology and highlighting the use of multi-tiered panels in neurological disease diagnosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-60872-3